Technical Analysis for NBIX - Neurocrine Biosciences, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 135.99 | -1.28% | -1.77 |
Earnings due: May 1
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Flat | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Fell Below 50 DMA | Bearish | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
20 DMA Support | Bullish | -1.28% | |
50 DMA Support | Bullish | -1.28% | |
MACD Bullish Signal Line Cross | Bullish | -2.14% | |
Multiple of Ten Bearish | Other | -2.14% | |
Upper Bollinger Band Touch | Strength | -2.14% | |
Shooting Star Candlestick | Bearish | -2.93% | |
Crossed Above 20 DMA | Bullish | -2.93% |
Alert | Time |
---|---|
20 DMA Support | about 22 hours ago |
50 DMA Support | about 22 hours ago |
60 Minute Opening Range Breakdown | about 23 hours ago |
Fell Below 50 DMA | about 23 hours ago |
Fell Below Previous Day's Low | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/01/2024
Neurocrine Biosciences, Inc. Description
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Clinical Development Diabetes Alcohol Disorders Cardiovascular Disease Schizophrenia Vascular Disease Epilepsy Hormones Ethers Movement Disorders Insomnia Transporter Type I Diabetes Endometriosis Essential Tremor Fibroids Type II Diabetes Uterine Fibroid Dyskinesia Gnrh Antagonists Neurocrine Biosciences
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 148.3699 |
52 Week Low | 89.04 |
Average Volume | 870,717 |
200-Day Moving Average | 121.39 |
50-Day Moving Average | 136.55 |
20-Day Moving Average | 136.46 |
10-Day Moving Average | 134.90 |
Average True Range | 4.27 |
RSI (14) | 48.72 |
ADX | 17.82 |
+DI | 21.41 |
-DI | 18.47 |
Chandelier Exit (Long, 3 ATRs) | 132.18 |
Chandelier Exit (Short, 3 ATRs) | 142.95 |
Upper Bollinger Bands | 142.21 |
Lower Bollinger Band | 130.72 |
Percent B (%b) | 0.46 |
BandWidth | 8.42 |
MACD Line | -0.32 |
MACD Signal Line | -0.56 |
MACD Histogram | 0.2434 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 141.18 | ||||
Resistance 3 (R3) | 141.48 | 140.06 | 140.32 | ||
Resistance 2 (R2) | 140.06 | 138.73 | 139.91 | 140.03 | |
Resistance 1 (R1) | 138.02 | 137.92 | 137.31 | 137.72 | 139.74 |
Pivot Point | 136.60 | 136.60 | 136.24 | 136.45 | 136.60 |
Support 1 (S1) | 134.56 | 135.27 | 133.85 | 134.26 | 132.24 |
Support 2 (S2) | 133.14 | 134.46 | 132.99 | 131.95 | |
Support 3 (S3) | 131.10 | 133.14 | 131.67 | ||
Support 4 (S4) | 130.80 |